Chirag N. Patel

Dr. Chirag N. Patel

Computer-Aided Drug Design Group, Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institute of Health, Frederick, MD, USA
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2017 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
CPChirag N. Patel
Chirag N. Patel
JGJohn J Georrge
John J Georrge
KMKrunal M. Modi
Krunal M. Modi
MNMoksha B. Narechania
Moksha B. Narechania
DPDaxesh P. Patel
Daxesh P. Patel
HPHimanshu A. Pandya
Himanshu A. Pandya
Alzheimer’s disease (AD) is one of the most significant neurodegenerative disorders and its symptoms mostly appear in aged people. Catechol-o-methyltransferase (COMT) is one of the known target enzymes responsible for AD. With the use of 23 known inhibitors of COMT, a query has been generated and validated by screening against the database of 1500 decoys to obtain the GH score and enrichment value. The crucial features of the known inhibitors were evaluated by the online ZINC Pharmer to identify new leads from a ZINC database. Five hundred hits were retrieved from ZINC Pharmer and by ADMET (absorption, distribution, metabolism, excretion, and toxicity) filtering by using FAF-Drug-3 and 36 molecules were considered for molecular docking. From the COMT inhibitors, opicapone, fenoldopam, and quercetin were selected, while ZINC63625100_413 ZINC39411941_412, ZINC63234426_254, ZINC63637968_451, and ZINC64019452_303 were chosen for the molecular dynamics simulation analysis having high binding affinity and structural recognition. This study identified the potential COMT inhibitors through pharmacophore-based inhibitor screening leading to a more complete understanding of molecular-level interactions.

13 October 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CPChirag N. Patel
Chirag N. Patel
SJSiddhi P. Jani
Siddhi P. Jani
DJDharmesh G. Jaiswal
Dharmesh G. Jaiswal
SKSivakumar Prasanth Kumar
Sivakumar Prasanth Kumar
NMNaman Mangukia
Naman Mangukia
HPHimanshu A. Pandya
Himanshu A. Pandya
Novel SARS-CoV-2, an etiological factor of Coronavirus disease 2019 (COVID-19), poses a great challenge to the public health care system. Among other druggable targets of SARS-Cov-2, the main protease (Mpro) is regarded as a prominent enzyme target for drug developments owing to its crucial role in virus replication and transcription. We pursued a computational investigation to identify Mpro inhibitors from a compiled library of natural compounds with proven antiviral activities using a hierarchical workflow of molecular docking, ADMET assessment, dynamic simulations and binding free-energy calculations. Five natural compounds, Withanosides V and VI, Racemosides A and B, and Shatavarin IX, obtained better binding affinity and attained stable interactions with Mpro key pocket residues. These intermolecular key interactions were also retained profoundly in the simulation trajectory of 100 ns time scale indicating tight receptor binding. Free energy calculations prioritized Withanosides V and VI as the top candidates that can act as effective SARS-CoV-2 Mpro inhibitors.



18 November 2022 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
CPChirag N. Patel
Chirag N. Patel
SJSiddhi P. Jani
Siddhi P. Jani
SKSivakumar Prasanth Kumar
Sivakumar Prasanth Kumar
KMKrunal Modi
Krunal Modi
YKYugesh Kumar
Yugesh Kumar

1 April 2017 in Journal of Luminescence
Verified
Journal Article
Closed access
UPUrvi Panchal
Urvi Panchal
KMKrunal Modi
Krunal Modi
SDShuvankar Dey
Shuvankar Dey
UPUsha Prajapati
Usha Prajapati
CPChirag N. Patel
Chirag N. Patel
VJV.K. Jain
V.K. Jain